| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Giselle Castaneira, Kelley Rojas, Yehuda Galili, Zachary Field, Ariel Perez-Perez, Mario Madruga, Steve J Carla. Idiopathic Thrombocytopenic Purpura Induced by Synthetic Cannabinoid. Journal of addiction medicine. vol 13. issue 3. 2020-06-25. PMID:30531235. |
k2/spice, or synthetic marijuana, acts on cannabinoid receptors cb1 (cannabinoid type-1) and cb2 (cannabinoid type-2) with increased binding capacity compared to marijuana. |
2020-06-25 |
2023-08-13 |
Not clear |
| Lara Milian, Manuel Mata, Javier Alcacer, María Oliver, María Sancho-Tello, José Javier Martín de Llano, Carlos Camps, José Galbis, Julian Carretero, Carmen Card. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PloS one. vol 15. issue 2. 2020-05-05. PMID:32049991. |
this necessitates the development of new complementary drugs, e.g., cannabinoid receptors (cb1 and cb2) agonists including tetrahydrocannabinol (thc) and cannabidiol (cbd). |
2020-05-05 |
2023-08-13 |
Not clear |
| David U Nagy, Kevin Cianfaglione, Filippo Maggi, Stefania Sut, Stefano Dall'Acqu. Chemical Characterization of Leaves, Male and Female Flowers from Spontaneous Cannabis (Cannabis sativa L.) Growing in Hungary. Chemistry & biodiversity. vol 16. issue 3. 2019-05-28. PMID:30548994. |
the results indicated that female inflorescence essential oil contains high amounts of the cb2 agonists, (e)-caryophyllene (28.3 %) and cannabidiol (cbd; 24.9 %), whereas leaves and male inflorescence essential oils contained lower amounts of both compounds. |
2019-05-28 |
2023-08-13 |
Not clear |
| Vincenzo Micale, Filippo Drag. Endocannabinoid system, stress and HPA axis. European journal of pharmacology. vol 834. 2018-12-18. PMID:30036537. |
the endocannabinoid system (ecs), which is composed of the cannabinoid receptors types 1 and 2 (cb1 and cb2) for marijuana's psychoactive ingredient ∆ |
2018-12-18 |
2023-08-13 |
Not clear |
| Patil Armenian, Michael Darracq, Jirair Gevorkyan, Shane Clark, Bryan Kaye, Nicklaus P Brandehof. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature. Neuropharmacology. vol 134. issue Pt A. 2018-11-07. PMID:29037744. |
due to full agonism at the cannabinoid receptors cb1 and cb2, clinical effects are more severe than marijuana, which is a partial cannabinoid receptor agonist. |
2018-11-07 |
2023-08-13 |
Not clear |
| Matthew R D Brown, W Paul Farquhar-Smit. Cannabinoids and cancer pain: A new hope or a false dawn? European journal of internal medicine. vol 49. 2018-10-25. PMID:29482740. |
the efficacy of cannabinoids seems to have been 'lost in translation' which may in part be related to using extracts of herbal cannabis rather than targeted selective full agonists at the cannabinoid cb1 and cb2 receptors. |
2018-10-25 |
2023-08-13 |
Not clear |
| Renata Androvicova, Jiri Horacek, Tibor Stark, Filippo Drago, Vincenzo Mical. Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon? Pharmacological research. vol 115. 2017-12-27. PMID:27884725. |
the endocannabinoid system (ecs), which is composed of the cannabinoid receptors types 1 and 2 (cb1 and cb2) for marijuana's psychoactive ingredient Δ |
2017-12-27 |
2023-08-13 |
Not clear |
| Małgorzata Pokrywka, Joanna Góralska, Bogdan Solnic. Cannabinoids - a new weapon against cancer? Postepy higieny i medycyny doswiadczalnej (Online). vol 70. issue 0. 2017-07-17. PMID:28100841. |
the isolation and characterization of the structure of one of the main active ingredients of cannabis - Δ9 - tetrahydrocannabinol as well the discovery of its cannabinoid binding receptors cb1 and cb2, has been a milestone in the study of the possibilities of the uses of cannabis sativa and related products in modern medicine. |
2017-07-17 |
2023-08-13 |
Not clear |
| Wen-Juan Huang, Wei-Wei Chen, Xia Zhan. Endocannabinoid system: Role in depression, reward and pain control (Review). Molecular medicine reports. vol 14. issue 4. 2017-04-05. PMID:27484193. |
in ancient times, this depression-pain comorbidity was treated using extracts of the cannabis sativa plant, known now as marijuana and the mode of action of Δ9‑tetrahydrocannabinol, the active cannabinoid ingredient of marijuana, has only recently become known, with the identification of cannabinoid receptor type 1 (cb1) and cb2. |
2017-04-05 |
2023-08-13 |
Not clear |
| Ester Aso, Pol Andrés-Benito, Margarita Carmona, Rafael Maldonado, Isidre Ferre. Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine. Journal of Alzheimer's disease : JAD. vol 51. issue 2. 2016-12-20. PMID:26890764. |
the aim of the present study was to evaluate the specific contribution of cb2 receptor to the progression of ad-like pathology and its role in the positive effect of a cannabis-based medicine (1:1 combination of Δ9-tetrahidrocannabinol and cannabidiol) previously demonstrated to be beneficial in the aβpp/ps1 transgenic model of the disease. |
2016-12-20 |
2023-08-13 |
mouse |
| Katarzyna Fijał, Małgorzata Fili. Clinical/Therapeutic Approaches for Cannabinoid Ligands in Central and Peripheral Nervous System Diseases: Mini Review. Clinical neuropharmacology. vol 39. issue 2. 2016-12-13. PMID:26818043. |
cannabinoids, the components of cannabis sativa linnaeus, interact with cb1 and cb2 receptors, which are located both in the central nervous system and in the periphery and thus may exert a widespread biological activity in the body. |
2016-12-13 |
2023-08-13 |
Not clear |
| Eric W Bow, John M Rimold. The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspectives in medicinal chemistry. vol 8. 2016-07-11. PMID:27398024. |
the cannabinoids are members of a deceptively simple class of terpenophenolic secondary metabolites isolated from cannabis sativa highlighted by (-)-Δ(9)-tetrahydrocannabinol (thc), eliciting distinct pharmacological effects mediated largely by cannabinoid receptor (cb1 or cb2) signaling. |
2016-07-11 |
2023-08-13 |
Not clear |
| K R Patil, S N Goyal, C Sharma, C R Patil, S Ojh. Phytocannabinoids for Cancer Therapeutics: Recent Updates and Future Prospects. Current medicinal chemistry. vol 22. issue 30. 2016-06-07. PMID:26179998. |
the ecs includes two g-protein-coupled receptors; the cannabinoid receptors-1 and -2 (cb1 and cb2) for marijuana's psychoactive principle Δ(9)-tetrahydrocannabinol (Δ(9)-thc), their endogenous small lipid ligands; namely anandamide (aea) and 2-arachidonoylglycerol (2-ag), also known as endocannabinoids and the enzymes for endocannabinoid biosynthesis and degradation such as fatty acid amide hydrolase (faah) and monoacylglycerol lipase (magl). |
2016-06-07 |
2023-08-13 |
Not clear |
| Bjorn Jensen, Jeffrey Chen, Tim Furnish, Mark Wallac. Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence. Current pain and headache reports. vol 19. issue 10. 2016-05-10. PMID:26325482. |
the two primary phytocannabinoids are delta-9-tetrahydrocannabinol (thc) and cannabidiol (cbd), with cb1 receptors in the brain and peripheral tissue and cb2 receptors in the immune and hematopoietic systems. |
2016-05-10 |
2023-08-13 |
Not clear |
| Susan Fung, Allison E Cherry, Cong Xu, Nephi Stell. Alkylindole-sensitive receptors modulate microglial cell migration and proliferation. Glia. vol 63. issue 10. 2016-05-03. PMID:25914169. |
cannabinoids, including the active component of the cannabis plant, tetrahydrocannabinol (thc), and the synthetic alkylindole (ai) compound, win55212-2 (win-2), activate two molecularly identified gpcrs: cb1 and cb2 . |
2016-05-03 |
2023-08-13 |
mouse |
| Sean D McAllister, Liliana Soroceanu, Pierre-Yves Despre. The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 10. issue 2. 2016-04-01. PMID:25916739. |
as a therapeutic agent, most people are familiar with the palliative effects of the primary psychoactive constituent of cannabis sativa (cs), Δ(9)-tetrahydrocannabinol (thc), a molecule active at both the cannabinoid 1 (cb1) and cannabinoid 2 (cb2) receptor subtypes. |
2016-04-01 |
2023-08-13 |
Not clear |
| Guy A Cabral, Thomas J Rogers, Aron H Lichtma. Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 10. issue 2. 2016-04-01. PMID:26054900. |
the major psychoactive phytocannabinoid found in cannabis ∆(9)-tetrahydrocannabinol (thc) produces the majority of its pharmacological effects through two cannabinoid receptors, termed cb1 and cb2. |
2016-04-01 |
2023-08-13 |
human |
| A Vigolo, A Ossato, C Trapella, F Vincenzi, C Rimondo, C Seri, K Varani, G Serpelloni, M Mart. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice. Neuropharmacology. vol 95. 2016-03-08. PMID:25769232. |
jwh-018 is a synthetic cb1 and cb2 agonist illegally marketed as products named "spice" or "herbal blend" for its psychoactive effects which are much higher than those produced by cannabis. |
2016-03-08 |
2023-08-13 |
mouse |
| Charu Sharma, Bassem Sadek, Sameer N Goyal, Satyesh Sinha, Mohammad Amjad Kamal, Shreesh Ojh. Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development. Evidence-based complementary and alternative medicine : eCAM. vol 2015. 2015-12-15. PMID:26664449. |
the cannabinoid molecules are derived from cannabis sativa plant which acts on the cannabinoid receptors types 1 and 2 (cb1 and cb2) which have been explored as potential therapeutic targets for drug discovery and development. |
2015-12-15 |
2023-08-13 |
Not clear |
| Sarah Rosenthaler, Birgit Pöhn, Caroline Kolmanz, Chi Nguyen Huu, Christopher Krewenka, Alexandra Huber, Barbara Kranner, Wolf-Dieter Rausch, Rudolf Moldzi. Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. Neurotoxicology and teratology. vol 46. 2015-11-16. PMID:25311884. |
focusing on the often presumed structure-affinity-relationship, ki values of phytocannabinoids cannabidiol (cbd), cannabidivarin (cbdv), cannabichromene (cbc), cannabigerol (cbg), cannabinol (cbn), thc acid (thca) and thc to human cb1 and cb2 receptors were detected by using competitive inhibition between radioligand [(3)h]cp-55,940 and the phytocannabinoids. |
2015-11-16 |
2023-08-13 |
human |